July 16, 2013
The health ministry asked the Kyoto Prefectural University of Medicine on July 12 to continue its investigation into a scandal-plagued clinical study on Novartis Pharma’s angiotensin receptor blocker Diovan (valsartan), following the university’s report concluding that the data used in...read more